Top

Journal of Ophthalmic Inflammation and Infection

Published in:

Open Access 01-12-2013 | Review

Eales' disease - current concepts in diagnosis and management

Authors: Jyotirmay Biswas, Reesha Karingattil Ravi, Angayarkanni Naryanasamy, Lily Therese Kulandai, Hajib Naraharirao Madhavan

Published in: Journal of Ophthalmic Inflammation and Infection | Issue 1/2013

Abstract

Eales' disease, first described by the British ophthalmologist Henry Eales in 1880, is characterized by three overlapping stages of venous inflammation (vasculitis), occlusion, and retinal neovascularization. Diagnosis is mostly clinical and requires exclusion of other systemic or ocular conditions that could present with similar retinal features. In recent years, immunological, molecular biological, and biochemical studies have indicated the role of human leukocyte antigen, retinal autoimmunity, Mycobacterium tuberculosis genome, and free radical-mediated damage in the etiopathogenesis of this disease. However, its etiology appears to be multifactorial. The management depends on the stage of the disease and consists of medical treatment with oral corticosteroids in the active inflammatory stage and laser photocoagulation in the advanced retinal ischemia and neovascularization stages.

Available only for authorised users

Eales H: Retinal haemorrhages associated with epistaxis and constipation. Brim Med 1880, 9: 262.

Patnaik B, Nagpul PN, Namperumalsamy P, Kalsi R: Eales disease-clinical features, pathophysiology, ethiopathogenesis. Ophthalmol Clin North Am 1998, 11: 601–617. 10.1016/S0896-1549(05)70081-XCrossRef

Saxena S, Kumar D: A new staging system for idiopathic retinal periphlebitis. Eur J Ophthalmol 2004,14(3):236–239.PubMed

Madhavan HN, Therese KL, Kavitha D: Further investigations on the association of Mycobacterium tuberculosis with Eales’ disease. Indian J Ophthalmol 2002, 50: 35–39.PubMed

Therese KL, Deepa P, Therese J, Bagyalakshmi R, Biswas J, Madhavan HN: Association of mycobacteria with Eales’ disease. Indian J Med Res 2007, 126: 56–62.PubMed

Singh R, Toor P, Parchand S, Sharma K, Gupta V, Gupta A: Quantitative polymerase chain reaction for Mycobacterium tuberculosis in so-called Eales’ disease. Ocul Immunol Inflamm 2012,20(3):153–157. 10.3109/09273948.2012.658134PubMedCrossRef

Elliot AJ: Recurrent intraocular haemorrhages in young adults, Eales' disease; a preliminary report. Treat Serv Bull 1949,4(7):35–42.PubMed

Gupta A, Gupta V, Arora S, Dogra MR, Bambery P: PCR-positive tubercular retinal vasculitis: clinical characteristics and management. Retina 2001,21(5):435–444. 10.1097/00006982-200110000-00004PubMedCrossRef

Ishaq M, Karamat S, Niazi MK: HLA typing in patients of Eales disease. J Coll Physicians Surg Pak 2005,15(5):288–290.PubMed

10.

Saxena S, Kumar D, Kapoor S, Jain A: C-reactive protein in Eales' disease. Ann Ophthalmol 2002, 34: 179–180. 10.1007/s12009-002-0071-zCrossRef

11.

Saxena S, Pant AB, Khanna VK, Agarwal AK, Singh K, Kumar D, Singh VK: Interleukin-1 and tumor necrosis factor-alpha: novel targets for immunotherapy in Eales disease. Ocul Immunol Inflamm 2009, 17: 201–206. 10.1080/09273940902731015PubMedCrossRef

12.

Sen A, Hussain I, Mukhopadhyay D, Paine SK, Mukherjee A, Mondal LK, Chatterjee M, Bhattacharya B: Increased toll-like receptor-2 expression on nonclassic CD16+ monocytes from patients with inflammatory stage of Eales' disease. Invest Ophthalmol Vis Sci 2011,52(9):6940–6948. 10.1167/iovs.11-7834PubMedCrossRef

13.

Sen A, Paine SK, Chowdhury IH, Mukherjee A, Choudhuri S, Saha A, Mandal LK, Bhattacharya B: Impact of IL-6 promoter polymorphism and serum IL-6 level on acute inflammation and neovascularization stage of patients with Eales' disease. Mol Vis 2011, 17: 2552–2563.PubMedCentralPubMed

14.

Rajesh M, Sulochana KN, Coral K, Punitham R, Biswas J, Babu K, Ramakrishnan S: Determination of carbonyl groups content in plasma proteins as a useful marker to assess the impairment in antioxidant defense in patients with Eales’ disease. Indian J Ophthalmol 2004, 52: 139–144.PubMed

15.

Rajesh M, Ramesh A, Ravi PE, Balakrishnamurthy P, Coral K, Punitham R, Sulochana KN, Biswas J, Ramakrishnan S: Accumulation of 8-hydroxydeoxyguanosine and its relationship with antioxidant parameters in patients with Eales’ disease: implications for antioxidant therapy. Curr Eye Res 2003, 27: 103–110. 10.1076/ceyr.27.2.103.15951PubMedCrossRef

16.

Rajesh M, Sulochana KN, Punitham R, Biswas J, Lakshmi S, Ramakrishnan S: Involvement of oxidative and nitrosative stress in promoting retinal vasculitis in patients with Eales’ disease. Clin Biochem 2003, 36: 377–385. 10.1016/S0009-9120(03)00058-4PubMedCrossRef

17.

Rajesh M, Sulochana KN, Ramakrishnan S, Biswas J, Manoharan PT: Iron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients with Eales’ disease: direct evidence using electron spin resonance spectroscopy. Curr Eye Res 2004, 28: 399–407. 10.1080/02713680490503723PubMedCrossRef

18.

Rajesh M, Sulochana KN, Sundaram AL, Krishnakumar S, Biswas J, Ramakrishnan S: Presence of a 88 kDa Eales protein in uveitis, tuberculosis, leprosy and rheumatoid arthritis. Med Sci Monit 2003,9(2):95–99.

19.

Selvi R, Angaayarkanni N, Bharathselvi M, Sivaramakrishna R, Anisha T, Jyotirmay B, Vasanthi B: Increase in Fe3+/Fe2+ ratio and iron induced oxidative stress in Eales’ disease and presence of Ferrous iron in circulating transferrin. Curr Eye Res 2007, 32: 677–683. 10.1080/02713680701486402PubMedCrossRef

20.

Sen A, Suman K, Chowdhury H, Mukherjee A, Choudhury S, Mandal L, Bhattacharya B: Assessment of gelatinase and tumor necrosis factor-α level in the vitreous and serum of patients with Eales’ disease. Retina 2011, 31: 1412–1420. 10.1097/IAE.0b013e318203c199PubMedCrossRef

21.

Ogata N, Tombran-tink J, Nishikawa M, Nishimura T, Mitsuma Y, Sakamoto T, Matsumura M: Pigment epithelium derived factor in the vitreous is low in diabetic retinopathy. J Ocul Biol Dis Inform 2009, 2: 20–28. 10.1007/s12177-009-9017-7CrossRef

22.

Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N: Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003, 46: 394–400.PubMed

23.

Angayarkanni N, Selvi R, Pukhraj R, Biswas J, Bhavesh SJ, Tombran-Tink J: Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease. J Ocul Biol Dis Inform 2009, 2: 20–28. 10.1007/s12177-009-9017-7CrossRef

24.

Tiwari A, Trivedi AC, Srivastava P, Pant AB, Saxena S: Comparative modeling of retinol-binding protein-3 and retinal S antigen in Eales’ disease and prediction of their binding sites using computational methods. J Ocul Biol Dis Inform 2010,3(3):88–91. 10.1007/s12177-011-9060-zCrossRef

25.

Abu El-Asrar AM, Al-Kharashi SA: Full panretinal photocoagulation and early vitrectomy improve prognosis of retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales’ disease). Br J Ophthalmol 2002, 86: 1248–1251. 10.1136/bjo.86.11.1248CrossRef

26.

Agrawal S, Agrawal J, Agrawal TP: Intravitreal triamcinolone acetonide in Eales disease. Retina 2006,26(2):227–229. 10.1097/00006982-200602000-00020PubMedCrossRef

27.

Selvi R, Angayarkanni N, Biswas J, Ramakrishnan S: Total antioxidant capacity in Eales’ disease, uveitis & cataract. Indian J Med Res 2011,134(1):83–90.PubMedCentralPubMed

28.

Saxena S, Srivastava P, Khanna VK: Antioxidant supplementation improves platelet membrane fluidity in idiopathic retinal periphlebitis (Eales' disease). J Ocul Pharmacol Ther 2010,26(6):623–626. 10.1089/jop.2010.0075PubMedCrossRef

29.

Ramakrishnan S, Sulochana KN, Lahshmi S, Selvi R, Angayarkanni N: Biochemistry of homocysteine in health and diseases. Indian J Biochem Biophys 2006, 43: 273–283.

30.

Ramakrishnan S, Selvi R, Saijyothi AV, Biswas J, Bharathselvi M: Clinical and biochemical benefits of oral administration of antioxidant vitamins E & C in patients with Eales disease. Biomedicine 2012. in press

31.

Kumar A, Tiwari HK, Sngh RP, Verma L, Prasad N: Comparative evaluation of early vs. deferred vitrectomy in Eales’ disease. Acta Ophthalmol Scand 2000, 78: 77–78. 10.1034/j.1600-0420.2000.078001077.xPubMedCrossRef

32.

Shukla D, Kanungo S, Prasad NM, Kim R: Surgical outcomes for vitrectomy in Eales’ disease. Eye 2008, 22: 900–904. 10.1038/sj.eye.6702763PubMedCrossRef

33.

Kumar A, Sinha S: Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol 2007,42(2):335–336. 10.3129/can j ophthalmol.i07-026PubMedCrossRef

34.

Kücxükerdönmez C, Akova YA, Yilmaz G: Intravitreal injection of bevacizumab in Eales disease. Ocul Immunol Inflamm 2008, 16: 63–65. 10.1080/09273940801923903CrossRef

35.

Chanana B, Azad RV, Patwardhan S: Role of intravitreal bevacizumab in the management of Eales’ disease. Int Ophthalmol 2010, 30: 57–61. 10.1007/s10792-009-9292-0PubMedCrossRef

36.

Raju B, Raju NS, Raju AS, Rajamma SP: Spontaneous relief of vitreomacular traction and regression of neovascularisation in Eales disease after intravitreal injection of bevacizumab. Retin Cases Brief Rep 2009, 3: 128–129. 10.1097/ICB.0b013e318178081aPubMedCrossRef

37.

Patwardhan SD, Azad R, Shah BM, Sharma Y: Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study. Retina 2011, 31: 866–870. 10.1097/IAE.0b013e3181f2a27fPubMedCrossRef

38.

Ishaq M, Niazi MK: Usefulness of laser photocoagulation in managing asymptomatic eyes of Eales disease. J Ayub Med Coll Abbottabad 2002,14(4):22–25.PubMed

39.

Asghar A, Niazi JH: Role of vitrectomy in the management of Eales’ disease. Pak J Ophthalmol 2007,23(1):1–5.

40.

Ishaq M, Niazi MK: Usefulness of pars plana vitrectomy in managing asymptomatic eyes of Eales' disease. J Ayub Med Coll Abbottabad 2003,15(1):50–53.PubMed

Title: Eales' disease - current concepts in diagnosis and management
Authors: Jyotirmay Biswas
Reesha Karingattil Ravi
Angayarkanni Naryanasamy
Lily Therese Kulandai
Hajib Naraharirao Madhavan
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Ophthalmic Inflammation and Infection / Issue 1/2013
Electronic ISSN: 1869-5760
DOI: https://doi.org/10.1186/1869-5760-3-11

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Eales' disease - current concepts in diagnosis and management

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

A diagnostic dilemma: infectious versus noninfectious multifocal choroiditis with panuveitis

Nocardia veterana endogenous endophthalmitis in a cardiac transplant patient

Cytomegalovirus anterior uveitis in immunocompetent individuals following topical prostaglandin analogues

Subconjunctival dexamethasone implant for non-necrotizing scleritis

Bacterial endophthalmitis caused by an intraocular cilium in a patient under treatment with infliximab

The microbiological profile of lacrimal abscess: two decades of experience from a tertiary eye care center